Business Description
![Edwards Lifesciences Corp Edwards Lifesciences Corp logo](https://static.gurufocus.com/logos/0C00000B3W.png?14)
Edwards Lifesciences Corp
NAICS : 339113
SIC : 3842
ISIN : BRE1WLBDR000
Share Class Description:
BSP:E1WL34: BRDRDescription
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.43 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.4 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 15.99 | |||||
Beneish M-Score | -1.85 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.4 | |||||
3-Year EBITDA Growth Rate | 20.6 | |||||
3-Year EPS without NRI Growth Rate | 11 | |||||
3-Year FCF Growth Rate | 0.3 | |||||
3-Year Book Growth Rate | 14.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 10.71 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.5 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 44.03 | |||||
9-Day RSI | 57.31 | |||||
14-Day RSI | 61.4 | |||||
6-1 Month Momentum % | 30.14 | |||||
12-1 Month Momentum % | 4.99 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.75 | |||||
Quick Ratio | 2.67 | |||||
Cash Ratio | 1.53 | |||||
Days Inventory | 269.57 | |||||
Days Sales Outstanding | 45.21 | |||||
Days Payable | 49.73 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.3 | |||||
Shareholder Yield % | 1.12 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 76.63 | |||||
Operating Margin % | 28.24 | |||||
Net Margin % | 23.01 | |||||
FCF Margin % | 4.08 | |||||
ROE % | 21.57 | |||||
ROA % | 15.33 | |||||
ROIC % | 22.28 | |||||
ROC (Joel Greenblatt) % | 57.06 | |||||
ROCE % | 20.09 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 39.79 | |||||
Forward PE Ratio | 34.01 | |||||
PE Ratio without NRI | 36.4 | |||||
Shiller PE Ratio | 51.03 | |||||
Price-to-Owner-Earnings | 445.99 | |||||
PEG Ratio | 2.07 | |||||
PS Ratio | 9.13 | |||||
PB Ratio | 7.81 | |||||
Price-to-Tangible-Book | 10.26 | |||||
Price-to-Free-Cash-Flow | 225.17 | |||||
Price-to-Operating-Cash-Flow | 106.61 | |||||
EV-to-EBIT | 33.7 | |||||
EV-to-Forward-EBIT | 29.27 | |||||
EV-to-EBITDA | 30.87 | |||||
EV-to-Forward-EBITDA | 26.13 | |||||
EV-to-Revenue | 8.89 | |||||
EV-to-Forward-Revenue | 8.31 | |||||
EV-to-FCF | 217.49 | |||||
Price-to-Projected-FCF | 3.14 | |||||
Price-to-DCF (Earnings Based) | 0.33 | |||||
Price-to-DCF (FCF Based) | 4.61 | |||||
Price-to-Median-PS-Value | 1 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.08 | |||||
Price-to-Graham-Number | 4.07 | |||||
Price-to-Net-Current-Asset-Value | 35.76 | |||||
Earnings Yield (Greenblatt) % | 2.97 | |||||
FCF Yield % | 0.45 | |||||
Forward Rate of Return (Yacktman) % | 18.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Edwards Lifesciences Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil R$) | 30,216.352 | ||
EPS (TTM) (R$) | 11.415 | ||
Beta | -0.24 | ||
Volatility % | 34.06 | ||
14-Day RSI | 61.4 | ||
14-Day ATR (R$) | 1.422518 | ||
20-Day SMA (R$) | 122.933 | ||
12-1 Month Momentum % | 4.99 | ||
52-Week Range (R$) | 76.4 - 129.61 | ||
Shares Outstanding (Mil) | 602.6 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Edwards Lifesciences Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Edwards Lifesciences Corp Stock Events
Event | Date | Price(R$) | ||
---|---|---|---|---|
No Event Data |
Edwards Lifesciences Corp Frequently Asked Questions
What is Edwards Lifesciences Corp(BSP:E1WL34)'s stock price today?
The current price of BSP:E1WL34 is R$126.24. The 52 week high of BSP:E1WL34 is R$129.61 and 52 week low is R$76.40.
When is next earnings date of Edwards Lifesciences Corp(BSP:E1WL34)?
The next earnings date of Edwards Lifesciences Corp(BSP:E1WL34) is 2024-07-26 Est..
Does Edwards Lifesciences Corp(BSP:E1WL34) pay dividends? If so, how much?
Edwards Lifesciences Corp(BSP:E1WL34) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |